Table 4 The effect of methotrexate on lipid profiles and cardiovascular risk parameters in male and female psoriatic patients

ApoA1, g/L

1.03 (0.16)

1.00 (0.13)

.0002

1.16 (0.19)

1.14 (0.17)

.1195

<.0001

ApoB, g/L

0.73 (0.17)

0.67 (0.15)

<.0001

0.72 (0.17)

0.69 (0.19)

.0214

.7756

TC, mmol/L

4.68 (0.85)

4.45 (0.83)

<.0001

4.94 (0.98)

4.76 (1.03)

.0083

.0241

TG, mmol/L

1.69 (1.06)

1.68 (1.66)

.1256

1.57 (1.10)

1.50 (1.14)

.1126

.3815

HDL-C, mmol/L

1.14 (0.26)

1.10 (0.23)

.0029

1.37 (0.32)

1.34 (0.31)

.1519

<.0001

LDL, mmol/L

2.94 (0.79)

2.79 (0.74)

.0001

2.95 (0.81)

2.87 (0.89)

.1342

.8775

Lp(a), mg/L

129.6 (148.6)

119.7 (143.9)

.0076

170.1 (195.7)

156.0 (191.8)

.0014

.0399

ApoB:ApoA1 ratio

0.72 (0.19)

0.69 (0.17)

.0001

0.64 (0.17)

0.62 (0.17)

.0762

.0004

TC:HDL-C ratio

4.26 (1.04)

4.18 (1.01)

.0512

3.76 (1.00)

3.68 (0.97)

.234

<.0001

LDL:HDL-C ratio

2.68 (0.84)

2.62 (0.82)

.1057

2.27 (0.77)

2.23 (0.79)

.4272

<.0001

LDL:ApoB ratio

4.04 (0.56)

4.13 (0.56)

.0019

4.09 (0.61)

4.13 (0.64)

.4161

.2722